UBS Group AG Acquires 1,222,690 Shares of ALT5 Sigma Corporation $AIFC

UBS Group AG boosted its holdings in shares of ALT5 Sigma Corporation (NASDAQ:AIFC) by 179.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,904,567 shares of the company’s stock after acquiring an additional 1,222,690 shares during the quarter. UBS Group AG owned 1.51% of ALT5 Sigma worth $2,095,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Crcm LP bought a new stake in ALT5 Sigma during the 3rd quarter worth approximately $6,220,000. FNY Investment Advisers LLC bought a new stake in ALT5 Sigma during the 3rd quarter worth approximately $64,000. Caitong International Asset Management Co. Ltd bought a new stake in ALT5 Sigma during the 3rd quarter worth approximately $98,000. Lantern Wealth Advisors LLC bought a new stake in ALT5 Sigma during the 3rd quarter worth approximately $36,000. Finally, Centiva Capital LP bought a new stake in ALT5 Sigma during the 3rd quarter worth approximately $626,000. 6.27% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered shares of ALT5 Sigma from a “sell” rating to a “strong sell” rating in a report on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

ALT5 Sigma Stock Performance

Shares of NASDAQ AIFC opened at $0.78 on Thursday. ALT5 Sigma Corporation has a 52-week low of $0.73 and a 52-week high of $10.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 0.82. The company’s 50 day moving average price is $1.02 and its 200-day moving average price is $1.43.

ALT5 Sigma (NASDAQ:AIFC) last issued its quarterly earnings results on Monday, May 18th. The company reported ($2.14) earnings per share (EPS) for the quarter. The firm had revenue of $4.71 million during the quarter. ALT5 Sigma had a negative return on equity of 68.25% and a negative net margin of 2,483.94%.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.